Coronaviruses were first identified in the mid-1960s and are named after the crown-like spikes on their surface. There are six different coronaviruses which can infect humans and cause illness. These comprise the four common coronaviruses; 229E and NL63 (alpha coronaviruses), OC43 and HKU1 (beta coronaviruses), and more recently, two other coronaviruses, MERS-CoV and SARS-CoV, both of which can cause severe illness.
The Native Antigen Company offers recombinant antigens and monoclonal antibodies for research into these coronaviruses, which remain a significant public health concern.
Human Coronavirus Background
People around the world commonly get infected with human coronaviruses 229E, NL63, OC43, and HKU1. However, occasionally coronaviruses that infect animals can evolve to become a new human coronavirus. Two recent examples of this are SARS-CoV and MERS-CoV (CDC).
Severe acute respiratory syndrome (SARS) is a lower respiratory tract illness that was first reported in patients from the Guandong Province of China, in November 2002. The causative agent, which was previously unknown, was isolated in 2003 and named as SARS coronavirus (SARS-CoV). The SARS coronavirus is an enveloped, single-stranded, positive RNA virus of the family, Coronoviridae (NCBI). The virus is thought to have a zoonotic origin, with the horseshoe bat being the primary natural reservoir, but this has not yet been confirmed. Mammals, including the palm civet, may act as intermediate hosts. In 2003, the SARS coronavirus spread rapidly and affected over 8,000 people in 26 countries. The rapid spread of SARS-CoV is thought to be due to person-to-person transmission of the virus via aerosol droplets or close contact with infected individuals. Since 2012, MERS-CoV has caused over 800 deaths in 27 countries with Saudi Arabia being the most affected (reviewed in Xu et al., 2019). The symptoms of SARS infection are like influenza and include fever, malaise, muscle pain, headache, diarrhoea and shivering. Clinical symptoms may also include coughing and shortness of breath. Respiratory distress may rapidly develop in some patients, resulting in death. SARS has a high rate of mortality and resulted in 774 deaths during the first epidemic in 2003. Currently, no licenced vaccine is available for the prevention of SARS infection. SARS continues to be of global health concern due to the rapid spread of the virus, the high mortality rate and the fears of a future SARS outbreak (WHO)
Middle East respiratory syndrome coronavirus (MERS-CoV) was first reported in 2012 after genome sequencing of a virus isolated from human sputum samples taken from a patient with flu-like symptoms and it has since spread rapidly (Al-Amri et al., 2017). Since 2012, MERS-CoV has caused over 800 deaths in 27 countries with Saudi Arabia being the most affected (Hashem et al., 2019). It is an acute respiratory disease and often leads to pneumonia and renal failure, very similar to severe acute respiratory syndrome (SARS) caused by another coronavirus, SARS-CoV. Like SARS-CoV, MERS-CoV is a zoonotic virus transmitted from animals to humans. The evolutionary origins of MERS-CoV are unknown but evidence suggests that insectivorous bats are likely to be the original source (Anthony et al., 2017). MERS-CoV and its neutralizing antibodies have also been detected in dromedary camels, which act as a reservoir host (Reusken et al., 2013) and both bat-to-human and camel-to-human transmission is possible. MERS-CoV is one of several viruses identified by WHO as a likely cause of a future epidemic and is listed for urgent research and development. The high case fatality rate, vaguely defined epidemiology, and absence of prophylactic or therapeutic measures against this novel virus have created an urgent need for an effective vaccine should an outbreak expand to pandemic proportions.
- Severe Acute Respiratory Syndrome Coronavirus, NCBI.
- Coronavirus. Centers for Disease Control and Prevention (CDC), 2019.
- SARS (Severe Acute Respiratory Syndrome). World Health Organization
- Anthony et al. (2017). Further Evidence for Bats as the Evolutionary Source of Middle East Respiratory Syndrome Coronavirus. Bio. 4;8(2).
- Wang et al. (2015). Evaluation of candidate vaccine approaches for MERS-CoV. Nat Commun. 28;6:7712.
- Reusken et al. (2013). Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect Dis. 13(10):859-66.
- Al-Amri et al. (2017). Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein. Sci Rep. 23;7:44875.
- Middle East respiratory syndrome coronavirus (MERS-CoV). World Health Organization.
- Xu et al. (2019). Antibodies and vaccines against Middle East respiratory syndrome coronavirus. Emerg Microbes Infect. 8(1): 841–856.
Human Coronavirus Antigens
We offer a range of Coronavirus antigens including recombinant proteins for SARS and MERS CoV. These antigens are suitable for use in assay development, vaccine research and as antigens for the preparation of Coronavirus-specific antibodies.
Human Coronavirus Antibodies
We offer monoclonal antibodies that are specific to SARS Coronavirus proteins, including SARS-CoV nucleoprotein, Envelope and Matrix protein and MERS-CoV Spike S1 protein.
Check out our FAQ section for answers to the most frequently asked questions about our website and company.